1 |
Wang B, Li R, Wu S, Liu X, Ren J, Li J, Bi K, Wang Y, Jia H. Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms. Front Oncol 2021;11:651541. [PMID: 34123801 DOI: 10.3389/fonc.2021.651541] [Reference Citation Analysis]
|
2 |
Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. Int J Cancer 2019;145:1179-88. [PMID: 30478914 DOI: 10.1002/ijc.32020] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 28.0] [Reference Citation Analysis]
|
3 |
Li F, Liu CS, Wu P, Ling AS, Pan Q, Li XN. CCT4 suppression inhibits tumor growth in hepatocellular carcinoma by interacting with Cdc20. Chin Med J (Engl) 2021;134:2721-9. [PMID: 34732665 DOI: 10.1097/CM9.0000000000001851] [Reference Citation Analysis]
|
4 |
Guarducci C, Bonechi M, Boccalini G, Benelli M, Risi E, Di Leo A, Malorni L, Migliaccio I. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. Breast Care (Basel) 2017;12:304-8. [PMID: 29234249 DOI: 10.1159/000484167] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
|